Helmholtz Gemeinschaft


Anti-cancer effects of bortezomib against chemoresistant neuroblastoma cell lines in vitro and in vivo

[thumbnail of 8172oa.pdf] PDF - Requires a PDF viewer such as GSview, Xpdf or Adobe Acrobat Reader

Item Type:Article
Title:Anti-cancer effects of bortezomib against chemoresistant neuroblastoma cell lines in vitro and in vivo
Creators Name:Michaelis, M., Fichtner, I., Behrens, D., Haider, W., Rothweiler, F., Mack, A., Cinatl, J., Doerr, H.W. and Cinatl, J.
Abstract:The proteasome inhibitor bortezomib (Velcade) was recently approved for the treatment of therapy-refractive multiple myeloma and is under investigation for numerous other types of cancer. A phase I clinical trial in paediatric patients resulted in tolerable toxicity. Since the emergence of chemoresistance represents one of the major drawbacks in cancer therapy, we investigated the influence of bortezomib on multi-drug resistant human neuroblastoma cell lines characterised by P-glycoprotein expression and p53 mutation. Nanomolar concentrations of bortezomib inhibited the cell cycle and induced apoptosis in chemosensitive as well as in chemoresistant cell lines. In vivo growth of chemosensitive and chemoresistant neuroblastoma cell lines was inhibited to a similar extent. In addition, bortezomib inhibited vessel formation in neuroblastoma xenografts. These findings and the favourable toxicity profile of bortezomib in children make it reasonable to further pursue additional development of the drug for the treatment of neuroblastoma and other paediatric solid tumours.
Keywords:Bortezomib, Chemoressistance, Doxorubicin, Multidrug Ressistance, Neuroblastoma, Vincristine
Source:International Journal of Oncology
Publisher:D.A. Spandidos
Page Range:439-446
Date:February 2006
Official Publication:https://doi.org/10.3892/ijo.28.2.439
PubMed:View item in PubMed

Repository Staff Only: item control page


Downloads per month over past year

Open Access
MDC Library